Fluvoxamine tested as treatment for long COVID fatigue in new trial
NCT ID NCT07359482
First seen Jan 29, 2026 · Last updated May 15, 2026 · Updated 13 times
Summary
This study tests whether fluvoxamine, a type of antidepressant, can reduce severe fatigue and other symptoms in people with long COVID. About 160 adults aged 18 to 70 who have been severely fatigued for at least 3 months after a COVID-19 infection will receive either fluvoxamine or a placebo for 12 weeks. The goal is to see if the drug improves fatigue, thinking problems, and other post-COVID issues.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for POST COVID-19 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Amsterdam UMC
Amsterdam-Zuidoost, 1105 AZ, Netherlands
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.